Koo

I have to listen to the presentation again - my first take is they are scrambling for $s at this MV level and hope to see a healthier biotech market before they do any deals other than operational financing to keep the lights on and pay salaries.

Any mention of financing was extremely vague - did you get any answers as to how they will finance these two trials? I came away with rights of first refusal, territorial licenses